[A16-77] Trifluridine/tipiracil (colorectal cancer) - Addendum to Commission A16-54
Last updated 02.02.2017
Project no.:
A16-77
Commission:
Commission awarded on 22.12.2016 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Accompanying information
Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.
| Project no. | Title | Status |
|---|---|---|
| A19-85 | Trifluridine/tipiracil (gastric cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A16-54 | Trifluridine/tipiracil (colorectal cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2017-02-02 A G-BA decision was published.